Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OmniComm Systems signs $2.5m deal with biotechnology company
TrialMaster EDC was selected in part for its Custom Data Export Utility. This enables compliance with the US Food and Drug Administration’s (FDA), soon to be mandated, requirement
TrialMaster EDC was selected in part for its Custom Data Export Utility. This enables compliance with the US Food and Drug Administration’s (FDA), soon to be mandated, requirement
The FDA guidance provides that the highest allowed dose will be 12mg daily. Repros is currently conducting a Phase II study for the use of Proellex in severe
Three of the four molecules it has designed are potent inhibitors of both cyclooxygenase-2 (COX-2) and COX-1 enzymes. The fourth inhibits COX-2 but only weakly inhibits COX-1. Simulations
The company plans to submit a protocol to the US Food and Drug Administration (FDA) in the first half of 2014 for a Phase I/II clinical trial to
Ferrer is Alexza’s commercial partner for Adasuve in the EU, Latin America and the Commonwealth of Independent States countries. Ferrer is commercializing the product in Romania through a
Saama Sales Operations Solution for Life Science is an integrated data and analytics platform that supports the drug commercialization process by automating sales operations and analytics. As part
BHV is a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate (remogliflozin) for type 2 diabetes and non-alcoholic steatohepatitis (NASH). Remogliflozin is currently in Phase II
This facility has been reconfigured to provide for 30 semi-private rooms to give each clinical trial volunteer a more comfortable experience for extended in-house stays. This dedicated clinical
This is the first application of Intravail in a solid dosage form. The Intravail formulation is compatible with current tableting processes employed for OTC and prescription drugs and
Burman’s knew that when these drugs hit the market, they were going to require intensive management in order to reach their potential for eliminating HCV in most patients.